Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results.
This study was conducted to investigate the feasibility and survival benefits of combined treatment with radiotherapy and temozolomide (TMZ), which has been covered by the national health insurance in Japanese patients with glioblastoma since September 2006. Between September 2006 and December 2011,...
Main Authors: | Takahiro Oike, Yoshiyuki Suzuki, Ken-ichi Sugawara, Katsuyuki Shirai, Shin-ei Noda, Tomoaki Tamaki, Masaya Nagaishi, Hideaki Yokoo, Yoichi Nakazato, Takashi Nakano |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3827088?pdf=render |
Similar Items
-
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma—A Critical Review
by: Ricardo J. Komotar M.D., et al.
Published: (2008-01-01) -
Molecular Evolution of a Glioblastoma Controlled With Tumor Treating Fields and Concomitant Temozolomide
by: H. Ian Robins, et al.
Published: (2018-10-01) -
Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
by: David Mills, et al.
Published: (2020-10-01) -
Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy
by: Georges Noël, et al.
Published: (2013-09-01) -
Slug, twist, and E-cadherin as immunohistochemical biomarkers in meningeal tumors.
by: Masaya Nagaishi, et al.
Published: (2012-01-01)